Special Situation Report Demerger – ITC Hotels Ltd by SBI Capitals

Given the attractive growth potential for domestic tourism industry and strong company financials, ITC Hotels has a long runway to capture the growth opportunities in the tourism industry. Investors can participate in the growth story of ITC’s hotel business by purchasing a minimum of 10 ITC shares on or before 03rd January, 2025. The average EV/EBITDA multiple of its industry peers (Indian Hotels & EIH Ltd) is 25.0x. Assuming that ITC Hotels will list at an EV/EBITDA multiple of 20.0x-30.0x, the share price of ITC Hotels Ltd is expected to list in the range of Rs 113 to Rs 170 per share

8 Stock picks for 2025. Nifty Expected to cross 28000 level by ICICI Direct

Our fair value for Nifty is pegged at 28,300 wherein we have valued the index at 21x PE on FY27E. Our Sensex target is pegged at 94,300. We see healthy double-digit upside in boarder markets in CY25

Lumax Auto Technologies is vrooming ahead. Buy for target price of ₹857 (36.9% upside): SMIFS

Lumax Auto Technologies Ltd (LATL) is one of India’s leading auto component manufacturers specialising in components such as head and tail lamps, air intake systems, plastic tanks, door panels, switches, sensors, actuators, antennas, gear shifter, two-wheeler frames, seating structures, swing arms and other aftermarket products

New Year Picks 2025: 9 Quality Stocks with up to 31% upside potential by Axis Securities

We continue to believe in the long-term growth story of the Indian equity market. However, with current valuations offering limited scope for further expansion, an increase in corporate earnings will be the primary driver of the market returns moving forward. Hence, bottom-up stock picking with a focus on ‘Growth at a Reasonable Price’ and ‘Quality’ would be keys to generating satisfactory returns in the next one year. We also suggest a “Buy on Dips” strategy in the stocks listed below with an investment horizon of over 12 months

Raymond Lifestyle has multiple growth drivers in place. Buy for target price of ₹3000 (49% upside): Motilal Oswal

RLL boasts a legacy of established brands such as Park Avenue, Raymond RTW, Parx, and Colorplus. However, the presence of RLL brands remain under-penetrated with 463 EBOs (including Ethnix EBOs).

PNB Housing is a strengthening franchise where the risk-reward profile is favorable for a long-term investor. Buy for target price of ₹1160 (38% upside): Motilal Oswal

PNBHF is pivoting its product mix toward the emerging and affordable housing segments, with both these relatively higher-yielding segments now contributing ~23% to the loan mix (compared to ~18% as of Mar’23). This pivot will gradually help the company secure a structural improvement in its blended yields and eventually deliver an expansion in its NIM profile.

Piramal Pharma is seeing strong momentum in CDMO. Buy for target price f ₹320 (27% upside): ICICI Direct

PPL owns 17 development and manufacturing facilities across India, US and UK with capabilities in sterile, API, formulations, drug discovery and manufacturing of nutrition products. The company holds 49% stake in AbbVie Therapeutics, JV with Allergan, and 33.33% in Yapan Bio which operates in the biologics / bio-therapeutics and vaccine segments

Hiren Ved has no Banking stocks in his portfolio. Ravi Dharamshi is very bullish about energy transition

Hiren Ved stated in his latest interview to CNBC TV18 that he has no Banking stocks in his portfolio because Banks are suffering a double whammy. On the one hand, they are unable to get cheap deposits from customers by way of FDs. At the same time, the RBI has imposed restrictions on their ability to give unsecured loans which was a highly profitable activity.

Protean eGov Technologies is a unique play on digital public infrastructure. Buy for target price of ₹2510 (24% upside): ICICI Direct

Protean eGov Technologies Ltd. (Protean), erstwhile known as NSDL e-Governance focuses on developing / modernising digital public infrastructure (DPI) and e-governance initiatives for various governmental bodies in India. Protean is a professionally managed company backed by several large financial institutions. Recently, NSE has sold its 20.31% stake, making Protean eligible to list on NSE

Saurabh Mukherjea’s Marcellus PMS Fund has added new stocks to the Kings of Capital, Rising Giants & Little Champs portfolios and exited Eureka Forbes

Saurabh Mukherjea says that the impact of slowing growth & NPA risks means that quality stocks in the Kings of Capital portfolio will thrive. He has added new stocks to the portfolio